GAMA
ACAD icon

Graticule Asia Macro Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Graticule Asia Macro Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5K Buy
+889
New +$19.6K ﹤0.01% 177
2017
Q1 		– Sell
-14,000
Closed -$404K – 122
2016
Q4 		$404K Buy
+14,000
New +$370K 0.05% 93

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Graticule Asia Macro Advisors's ACAD Position: Q2 2026 in Review

Graticule Asia Macro Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 889 shares worth $22.5K. The stake represents ﹤0.01% of the portfolio and ranks #177 among its holdings. This is a return to the name: Graticule Asia Macro Advisors previously reported a position in ACAD as recently as Q4 2016.

Graticule Asia Macro Advisors first reported a position in ACAD in Q4 2016 and has held it in 2 quarters since. The position peaked at $404K in Q4 2016. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Graticule Asia Macro Advisors held 889 shares of Acadia Pharmaceuticals worth $22.5K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Graticule Asia Macro Advisors position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Graticule Asia Macro Advisors's portfolio in Q2 2026, its #177 holding.
  • Graticule Asia Macro Advisors first reported a position in Acadia Pharmaceuticals in Q4 2016 and has held it in 2 quarters since.
  • Graticule Asia Macro Advisors's Acadia Pharmaceuticals position peaked at $404K in Q4 2016.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Graticule Asia Macro Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.